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ABSTRACT
This study assessed the age and gender distribu-
tion of Chlamydia trachomatis infections among
patients attending two clinics for sexually trans-
mitted diseases (STDs) in Slovenia. Between
January 1999 and December 2003, 1714 hetero-
sexual male and 892 heterosexual female patients
were tested for C. trachomatis. The prevalence of
C. trachomatis infection was 19.5% (n = 334) for
male patients and 10.7% (n = 96) for female
patients, with the highest prevalence in the group
aged 15–30 years. The prevalence decreased
between 2000 and 2003 among female patients.
The results support the implementation of routine
screening for C. trachomatis genital infection
among male and female patients aged < 30 years
attending STD clinics in Slovenia.
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Chlamydia trachomatis has been recognised as a
major bacterial sexually transmitted disease (STD)
in north America and western Europe [1]. The
prevalence of infection for men in STD settings is
15–20%, with a corresponding ﬁgure for women
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of > 20% [2,3]. C. trachomatis accounts for 30–50%
of non-gonococcal urethritis in men [4], and
C. trachomatis genital infections impose a signiﬁ-
cant disease burden in women, in whom they can
cause serious complications such as pelvic inﬂam-
matory disease, ectopic pregnancy and infertility
[5].
In Slovenia, the prevalence of C. trachomatis
infection among asymptomatic sexually active
young (18–24 years) adults is substantial,
amounting to 4.7% in both genders [6], while
the prevalence of asymptomatic chlamydial
urethritis among a group of military recruits
(mean age, 19.8 years) from the Celje region was
2.6% [7]. However, little information is available
regarding the prevalence of C. trachomatis infec-
tion among patients attending STD clinics for
medical care in Slovenia. The present report
describes a 5-year survey of C. trachomatis infec-
tion in heterosexual male and female patients
attending two STD clinics in Ljubljana, the capital
city of Slovenia.
The study sample comprised 1714 consecutive
heterosexual male patients and 892 female
patients (age range, 15–59 years) who sought
medical care from the two STD clinics between
January 1999 and December 2003. The male
patients had symptoms and signs of urethritis,
with mild-to-severe dysuria and discomfort in
the urethra, and a clear-to-whitish or mucopu-
rulent discharge. Female patients were mostly
asymptomatic. The patients were advised not
to urinate for 3 h before examination. At least
two simultaneous Dacron swab (Meus, Piove
di Sacco, Italy) samples were taken from the
urethral meatus of male patients, and from
the endocervix and urethra of female patients.
The ﬁrst swab was rolled onto a MicroTrak
slide (Trinity Biotech, Wicklow, Ireland), while
the second swab was placed in 1.5 mL of 2 M
sucrose phosphate (2SP) Chlamydia transport
medium, prepared in our laboratory, for culture
and PCR. The swab specimens for culture and
PCR were frozen at ) 70C until required for
testing.
All samples were examined by the MicroTrak
(Trinity Biotech) direct ﬂuorescent antibody
(DFA) test and were also cultured. A sample
was considered positive if at least ten chlamy-
dial elementary bodies were observed in the
specimen by the DFA test, or if at least one
inclusion body of C. trachomatis was observed
following the addition of speciﬁc monoclonal
antibodies (Trinity Biotech) to cycloheximide-
treated McCoy cells. In 537 cases, the results of
the two tests were inconclusive, either because
of the small number of elementary bodies (< ten)
found by DFA, non-speciﬁc ﬂuorescence, an
excess of mucus in the sample, or destruction
of cells observed in culture. For these 537
samples, the Amplicor PCR assay (Roche
Diagnostic Systems, Basel, Switzerland) was
performed. Internal control target DNA was
included in each PCR run to monitor the
inhibition of ampliﬁcation. The PCR results were
interpreted according to the recommendations of
the manufacturer.
C. trachomatis infection was diagnosed in 334
(19.5%) of the 1714 male patients, and in 96
(10.7%) of the 892 female patients (Table 1). The
prevalence of C. trachomatis infection peaked in
the group aged 21–30 years in both genders
(26.2% for male patients, 16.7% for female
patients) and decreased thereafter with increased
age. The observed prevalence, as documented
by age and gender, was in accordance with
previous ﬁndings [8–10]. In the USA, nearly
75% of all new cases occur in women aged
< 25 years, while non-gonococcal urethritis is the
most commonly diagnosed STD in men [11].
Sexually active adolescents and young adults are
particularly susceptible to genital chlamydial
infections because of their greater rate of exposure
to high-risk sexual behaviour [12]. Moreover, the
frequent spread of Chlamydia to regular female
partners is not unexpected, because the symp-
toms are often mild or even absent for a long
period [1].
The overall prevalence of C. trachomatis
showed a decreasing trend after the year 2000
(Fig. 1). This might be associated with a change
Table 1. Prevalence of genital Chlamydia trachomatis infec-
tion by age group among patients attending two sexually
transmitted disease clinics in Slovenia (1999–2003)
Age group
Male patients Female patients
No.
tested
No.
positive
Prevalence
(%)
No.
tested
No.
positive
Prevalence
(%)
15–20 101 23 22.7 98 11 11.2
21–30 729 191 26.2 406 68 16.7
31–40 469 89 18.9 222 14 6.3
41–50 274 26 9.5 115 3 2.6
> 51 141 5 3.5 51 0 0
Total 1714 334 19.5 892 96 10.7
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in sexual behaviour following mass health edu-
cation campaigns. A relatively higher prevalence
of C. trachomatis infection was observed among
male as opposed to female patients. However,
this gender difference does not necessarily
reﬂect a true difference in the epidemiology of
C. trachomatis infection. The higher rates of
positivity in male patients could reﬂect the
increased rates of testing in males attending
the STD outpatient clinics, as female patients
usually prefer to visit their gynaecologist for
testing. In Sweden, a relatively larger proportion
of male cases has also been reported, and the
female-to-male ratio of notiﬁed C. trachomatis
infections has declined, which reﬂects increased
testing of male patients [2].
In the present study, culture and DFA were
performed for all patient samples, while PCR
was performed only for 537 samples for which
the results of DFA and ⁄ or culture were doubtful.
However, the sensitivity of DFA has been
estimated at 89.8%, and that of culture at
83.8%. DFA results with < ten elementary bodies
were positive by PCR in 18 (3.4%) culture-
negative cases, and in nine (1.7%) DFA- and
culture-negative specimens. The remaining 510
samples were negative by PCR. These data
indicate that the true prevalence of C. trachomatis
infections might have been higher than that
observed.
The results of this study strongly support
the implementation of routine testing for
C. trachomatis among men and women who
attend STD clinics in Slovenia. The treatment of
positive patients, and the tracing, screening and
treatment of the sexual partners of infected
individuals, are two important goals. The possible
severe complications of untreated asymptomatic
C. trachomatis infections mean that routine screen-
ing programmes should be considered in Slovenia
for C. trachomatis infections among at least the
sexually active population aged < 30 years.
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Fig. 1. Annual prevalence of Chlamydia trachomatis infec-
tion among patients attending two sexually transmitted
disease clinics in Slovenia (1999–2003).
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